Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.

Ashida A, Takata M, Murata H, Kido K, Saida T.

Int J Cancer. 2009 Feb 15;124(4):862-8. doi: 10.1002/ijc.24048.

2.

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.

Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R.

Dermatology. 2010;220(1):77-81. doi: 10.1159/000265558. Review.

3.

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

Smalley KS, Sondak VK, Weber JS.

Histol Histopathol. 2009 May;24(5):643-50. doi: 10.14670/HH-24.643. Review.

PMID:
19283671
4.

Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.

Papaspyrou G, Garbe C, Schadendorf D, Werner JA, Hauschild A, Egberts F.

Melanoma Res. 2011 Dec;21(6):475-82. doi: 10.1097/CMR.0b013e32834b58cf. Review.

PMID:
21897303
5.

Therapeutic implications of KIT in melanoma.

Postow MA, Carvajal RD.

Cancer J. 2012 Mar-Apr;18(2):137-41. doi: 10.1097/PPO.0b013e31824b2404. Review.

PMID:
22453014
6.

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Woodman SE, Davies MA.

Biochem Pharmacol. 2010 Sep 1;80(5):568-74. doi: 10.1016/j.bcp.2010.04.032. Review.

7.

Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.

Takata M, Murata H, Saida T.

Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71. doi: 10.1111/j.1755-148X.2009.00645.x. Review.

PMID:
19788535
8.

NUAK2: an emerging acral melanoma oncogene.

Namiki T, Coelho SG, Hearing VJ.

Oncotarget. 2011 Sep;2(9):695-704. Review.

9.

KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.

Tay CM, Ong CW, Lee VK, Pang B.

Pathology. 2013 Feb;45(2):127-37. doi: 10.1097/PAT.0b013e32835c7645. Review.

PMID:
23277171
10.

A potential role for nilotinib in KIT-mutated melanoma.

Tran A, Tawbi HA.

Expert Opin Investig Drugs. 2012 Jun;21(6):861-9. doi: 10.1517/13543784.2012.679341. Review.

PMID:
22500535
11.

Primary dermal melanoma: A case report and molecular characterization.

Hida Y, Kubo Y, Miyajima O, Arase S.

J Dermatol. 2009 Jun;36(6):346-52. doi: 10.1111/j.1346-8138.2009.00650.x. Review.

PMID:
19500183
12.

The potential role of sunitinib targeting melanomas.

Valsecchi ME, Sato T.

Expert Opin Investig Drugs. 2013 Nov;22(11):1473-83. doi: 10.1517/13543784.2013.837449. Review.

PMID:
24050392

Supplemental Content

Support Center